Genfit reported first-half 2025 results and a strategic refocus in liver disease. The company ended June with €107.5 million in cash and cash equivalents, excluding a €26.5 million milestone received in July tied to pricing and reimbursement of elafibranor (IQIRVO) in three major European markets. First-half revenues totaled €35.7 million, driven by the milestone and €6.9 million in royalties from IQIRVO sales. The period closed with a €10.0 million net loss, reflecting financing costs linked to a royalty deal. Operationally, Genfit discontinued VS-01 in acute-on-chronic liver failure and will redirect the asset toward urea cycle disorder, while accelerating four other ACLF programs. Near-term catalysts include phase 1b data for GNS561 in cholangiocarcinoma and initial safety and pharmacodynamic signals for G1090N by year-end.
The pivot underscores a calculated trade-off: Genfit is swapping near-term P&L optics for balance-sheet runway and pipeline optionality. A non-dilutive royalty financing closed earlier this year extends projected cash runway beyond 2028, even as it weighs on the income statement. That liquidity, combined with the acquisition of full IP rights to GNS561, suggests a company building leverage across multiple shots on goal rather than anchoring to a single program. The real test will be converting that optionality into proof-of-concept wins in ACLF, a high-need, high-risk arena with no approved therapies and complex endpoints.
For Commercial teams, the PBC market is in flux. IQIRVO’s uptake is accelerating in the U.S. and Europe, and the FDA-requested withdrawal of obeticholic acid in the U.S. removes the legacy second-line incumbent. The opening favors IQIRVO in the short term, but durability will depend on how quickly prescribers switch, how payers recalibrate formularies, and whether new entrants reach the market. If elafibranor secures a label expansion into primary sclerosing cholangitis on the back of favorable phase 2 data presented this year, the brand could compound its advantage across cholestatic liver diseases. Medical Affairs will need to partner with hepatology centers to manage therapy transitions from OCA, generate real-world evidence on biochemical response and pruritus, and clarify sequencing for patients on ursodeoxycholic acid with inadequate response.
The ACLF bet aligns with broader biopharma patterns: capital-light structures, royalty-backed financing to extend runways without dilution, and aggressive pipeline pruning to concentrate on the highest-impact assets. It also reflects a widening industry focus on hepatic emergencies and complications of cirrhosis, where hospital-based care, multi-organ interactions, and short decision windows complicate trial design and payer adoption. Success will require early alignment with regulators on clinically meaningful endpoints, pragmatic site selection to accelerate enrollment, and health-economic models that quantify avoided hospitalizations and ICU days.
The next six quarters will be decisive. Can Genfit and its partner translate the OCA market exit into durable IQIRVO leadership before the next wave of PBC challengers arrives, and will elafibranor’s PSC data catalyze a second growth pillar? Equally, can Genfit deliver convincing ACLF and CCA readouts by end-2025 to validate its portfolio approach and justify continued investment in an area where clinical risk is high but first-mover advantage could be substantial?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
